Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check13 days agoChange DetectedA site-wide NIH notice about terminology changes appears above the ClinicalTrials.gov page.SummaryDifference1%

- Check20 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedThe site footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check48 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record content. Access to the study details is blocked and the expected content is not visible.SummaryDifference19%

- Check62 days agoChange DetectedNo additions or deletions were provided in the site changes data, so there is no update to report for this page.SummaryDifference0.0%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.